Related references
Note: Only part of the references are listed.Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
Hong-Yue Lai et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression
Li-Fang Chou et al.
BIOMOLECULES (2020)
Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
Yolanda Augustin et al.
PHARMACOLOGY & THERAPEUTICS (2020)
FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression
Guohui Hu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling
Yujie Li et al.
ARCHIVES OF TOXICOLOGY (2019)
FoxM1: Repurposing an oncogene as a biomarker
Deeptashree Nandi et al.
SEMINARS IN CANCER BIOLOGY (2018)
FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1
Na Chai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
K. Lohitesh et al.
CANCER CELL INTERNATIONAL (2018)
Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma
Chuan Tian et al.
GENE THERAPY (2018)
Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer
Maxime Mermod et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Apoptosis: A Target for Anticancer Therapy
Claire M. Pfeffer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Clnicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis
Chaojie Liang et al.
ONCOTARGETS AND THERAPY (2018)
Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
Otilia Menyhart et al.
ROYAL SOCIETY OPEN SCIENCE (2018)
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
Renata A. Tassi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells
N. Yang et al.
ONCOGENE (2017)
Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer
Jing Zhang et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2017)
FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas
David Milewski et al.
PLOS GENETICS (2017)
Cancer combination therapies with artemisinin-type drugs
Thomas Efferth
BIOCHEMICAL PHARMACOLOGY (2017)
m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program
Sicong Zhang et al.
CANCER CELL (2017)
Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
Archana Bhaw-Luximon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells
Renyu Lin et al.
CANCER LETTERS (2016)
Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular Injury
Xiaojia Huang et al.
CIRCULATION (2016)
β-Catenin and Kras/Foxm1 Signaling Pathway Are Critical to Restrict Sox9 in Basal Cells During Pulmonary Branching Morphogenesis
Vladimir Ustiyan et al.
DEVELOPMENTAL DYNAMICS (2016)
Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis
Jianguang Jia et al.
MOLECULAR MEDICINE REPORTS (2016)
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1
Ji-chao Wei et al.
ACTA PHARMACOLOGICA SINICA (2015)
FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance
Gabriela Nestal de Moraes et al.
CELLULAR SIGNALLING (2015)
Oncogenic Human Papillomavirus 16E7 modulates SUMOylation of FoxM1b
Neha Jaiswal et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2015)
FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma
Fan-Di Meng et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2
Yeri Lee et al.
PLOS ONE (2015)
Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth
T. Chen et al.
CANCER GENE THERAPY (2014)
Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo
Judong Luo et al.
RADIATION ONCOLOGY (2014)
Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition
Michael V. Gormally et al.
NATURE COMMUNICATIONS (2014)
Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib
Trevan D. Fischer et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix et al.
EUROPEAN JOURNAL OF CANCER (2013)
Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis
Yuqi Cai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel
Xiaoxiao Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Involvement of FoxM1 in Non-Small Cell Lung Cancer Recurrence
Nuo Xu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
A Novel FoxM1-Caveolin Signaling Pathway Promotes Pancreatic Cancer Invasion and Metastasis
Chen Huang et al.
CANCER RESEARCH (2012)
FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51
Nu Zhang et al.
CLINICAL CANCER RESEARCH (2012)
FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis
Nu Zhang et al.
CANCER CELL (2011)
FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria
Hongcheng Sun et al.
CANCER LETTERS (2011)
FoxM1: A Master Regulator of Tumor Metastasis
Pradip Raychaudhuri et al.
CANCER RESEARCH (2011)
Multiple faces of FoxM1 transcription factor Lessons from transgenic mouse models
Tanya V. Kalin et al.
CELL CYCLE (2011)
Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
G. Portella et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells
Jin-Jian Lu et al.
INVESTIGATIONAL NEW DRUGS (2011)
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton
Nagaratna S. Hegde et al.
NATURE CHEMISTRY (2011)
Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells
Tan Weifeng et al.
PHYTOMEDICINE (2011)
Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro
Qi-fei Wu et al.
ACTA PHARMACOLOGICA SINICA (2010)
FoxM1 Mediates Resistance to Herceptin and Paclitaxel
Janai R. Carr et al.
CANCER RESEARCH (2010)
Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents
Devdutt Chaturvedi et al.
CHEMICAL SOCIETY REVIEWS (2010)
FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells
Jimmy M. -M. Kwok et al.
MOLECULAR CANCER RESEARCH (2010)
Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence
D. R. Littler et al.
NUCLEIC ACIDS RESEARCH (2010)
FOXM1 is a transcriptional target of ERa and has a critical role in breast cancer endocrine sensitivity and resistance
J. Millour et al.
BREAST CANCER RESEARCH (2010)
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
Ursula B. McGovern et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
FoxM1 Is a General Target for Proteasome Inhibitors
Uppoor G. Bhat et al.
PLOS ONE (2009)
Deletion of Forkhead Box M1 Transcription Factor from Respiratory Epithelial Cells Inhibits Pulmonary Tumorigenesis
I-Ching Wang et al.
PLOS ONE (2009)
Experimental therapy of hepatoma with artemisinin and its derivatives:: In vitro and in vivo activity, chemosensitization, and mechanisms of action
Junmei Hou et al.
CLINICAL CANCER RESEARCH (2008)
Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation
Ikuhiko Nakase et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy
Toshiro Masuda et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY (2008)
From traditional Chinese medicine to rational cancer therapy
Thomas Efferth et al.
TRENDS IN MOLECULAR MEDICINE (2007)
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment
Galina A. Gusarova et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation
George Notas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2006)
The history of qing hao in the Chinese materia medica
E Hsu
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2006)
Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice
TV Kalin et al.
CANCER RESEARCH (2006)
Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer
Yoshiaki Yamamoto et al.
ONCOLOGY (2006)
Antimalarial drug synergism and antagonism: Mechanistic and clinical significance
A Bell
FEMS MICROBIOLOGY LETTERS (2005)
Forkhead box m1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase
IC Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Silibinin efficacy against human hepatocellular carcinoma
L Varghese et al.
CLINICAL CANCER RESEARCH (2005)
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor
VV Kalinichenko et al.
GENES & DEVELOPMENT (2004)
A medicinal chemistry perspective on artemisinin and related endoperoxides
PM O'Neill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Skp2 is oncogenic and overexpressed in human cancers
M Gstaiger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
